Veerisa Vimolchalao1,2, Siwat Sakdejayont1,2,3, Ploytuangporn Wongchanapai2, Shama Sukprakun4, Pattama Angspatt2, Wilai Thawinwisan5, Piyachut Chenaksara5, Virote Sriuranpong1, Chanida Vinayanuwatikun1, Napa Parinyanitikun1, Nattaya Poovorawan2, Suebpong Tanasanvimon6. 1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand. 2. Division of Medical Oncology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 3. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. 4. Oncology Section, Production Division, Pharmacy Department, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 5. Department of Nursing, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 6. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand. surbpong@yahoo.com.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC). METHODS: In this randomized, double-blind, placebo-controlled, crossover study, we randomly assigned chemotherapy-naïve patients receiving HEC to receiveolanzapine or placebo in addition to ondansetron and dexamethasone. All subjects were crossed over to another treatment arm on second-cycle chemotherapy. The primary endpoint was complete response (CR) rate defined as no vomiting and no use of rescue drugs. RESULTS: At the first cycle, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (68.7% vs. 25.0%, p < 0.001), acute phase (0-24 h) (75.0% vs. 31.2%, p < 0.001) and delayed phase (24-120 h) (68.7% vs. 43.7%, p = 0.038). After crossover, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (67.2% vs. 25.0%, p < 0.001), acute phase (71.9% vs. 32.8%, p < 0.001) and delayed phase (67.2% vs. 37.5%, p < 0.001). In crossover analysis, the olanzapine group had significantly lower mean nausea (1.28 vs. 3.05, p < 0.001) and fatigue (3.5 vs. 4.58, p < 0.001) scores but higher mean appetite (2.5 vs. 1.55, p = 0.003) and sleepiness (3.26 vs. 2.2, p < 0.001) scores. There were no grade 3 and 4 anti-emetic-drug-related toxicities. Mean QT interval changes did not different between two groups (-4.30 vs. -1.86, p = 0.69). CONCLUSION: The addition of olanzapine to ondansetron and dexamethasone significantly improved CINV prevention and was safe in patients receiving HEC.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC). METHODS: In this randomized, double-blind, placebo-controlled, crossover study, we randomly assigned chemotherapy-naïve patients receiving HEC to receive olanzapine or placebo in addition to ondansetron and dexamethasone. All subjects were crossed over to another treatment arm on second-cycle chemotherapy. The primary endpoint was complete response (CR) rate defined as no vomiting and no use of rescue drugs. RESULTS: At the first cycle, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (68.7% vs. 25.0%, p < 0.001), acute phase (0-24 h) (75.0% vs. 31.2%, p < 0.001) and delayed phase (24-120 h) (68.7% vs. 43.7%, p = 0.038). After crossover, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (67.2% vs. 25.0%, p < 0.001), acute phase (71.9% vs. 32.8%, p < 0.001) and delayed phase (67.2% vs. 37.5%, p < 0.001). In crossover analysis, the olanzapine group had significantly lower mean nausea (1.28 vs. 3.05, p < 0.001) and fatigue (3.5 vs. 4.58, p < 0.001) scores but higher mean appetite (2.5 vs. 1.55, p = 0.003) and sleepiness (3.26 vs. 2.2, p < 0.001) scores. There were no grade 3 and 4 anti-emetic-drug-related toxicities. Mean QT interval changes did not different between two groups (-4.30 vs. -1.86, p = 0.69). CONCLUSION: The addition of olanzapine to ondansetron and dexamethasone significantly improved CINV prevention and was safe in patients receiving HEC.
Authors: Michael J Berger; David S Ettinger; Jonathan Aston; Sally Barbour; Jason Bergsbaken; Philip J Bierman; Debra Brandt; Dawn E Dolan; Georgiana Ellis; Eun Jeong Kim; Steve Kirkegaard; Dwight D Kloth; Ruth Lagman; Dean Lim; Charles Loprinzi; Cynthia X Ma; Victoria Maurer; Laura Boehnke Michaud; Lisle M Nabell; Kim Noonan; Eric Roeland; Hope S Rugo; Lee S Schwartzberg; Bridget Scullion; John Timoney; Barbara Todaro; Susan G Urba; Dorothy A Shead; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2017-07 Impact factor: 11.908
Authors: Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman Journal: J Clin Oncol Date: 2017-07-31 Impact factor: 44.544
Authors: David L DeRemer; Amber B Clemmons; Julianne Orr; Stephen Michael Clark; Arpita Shah Gandhi Journal: Pharmacotherapy Date: 2016-02 Impact factor: 4.705
Authors: Costantine Albany; Mary J Brames; Christopher Fausel; Cynthia S Johnson; Joel Picus; Lawrence H Einhorn Journal: J Clin Oncol Date: 2012-08-20 Impact factor: 44.544
Authors: Ronald Chow; Jørn Herrstedt; Matti Aapro; Leonard Chiu; Henry Lam; Elizabeth Prsic; Michael Lock; Carlo DeAngelis; Rudolph M Navari Journal: Support Care Cancer Date: 2021-01-13 Impact factor: 3.359